Wall Street Zen Raises Monopar Therapeutics' Stock Rating

Summary

Wall Street Zen has upgraded the rating of Monopar Therapeutics (NASDAQ: MNPR) from ‘Sell’ to ‘Hold.’ Other analysts have provided ratings as well: Piper Sandler maintains an ‘Overweight’ rating with a price target of $76, while HC Wainwright sets a target of $40. The average rating for the stock is ‘Moderate Buy’ with a consensus price target of $55.33. Recently, MNPR traded at $35.35 with a market cap of $216.17 million. The company is focused on developing cancer treatment drugs, with its main product in clinical trials.Market Beat

Impact Analysis

The event is classified at the company level, as it involves a specific stock rating change for Monopar Therapeutics. The upgrade from Wall Street Zen reflects a shift in sentiment about the company’s prospects, potentially due to positive developments or reassessments of its clinical trials and financial outlook. The direct impact is likely an increase in investor confidence, which could lead to upward pressure on MNPR’s stock price. Piper Sandler’s higher price target of $76 suggests optimism about the company’s future performance, possibly driven by expectations of successful trial outcomes or new market opportunities. HC Wainwright’s more conservative target of $40 indicates some caution, perhaps reflecting financial challenges such as increased net losses reported in the recent Q1 2025 financials.Reuters+ 2 Investors might see this as an opportunity to reassess their positions, considering both the potential upside and the risks associated with the company’s financial health and product pipeline.